Sana Biotechnology plans EASD 2026 symposium presentation on hypoimmune islet transplant without immunosuppression
PUBT · 3d ago
Share
Listen to the news
- Sana set an October 2, 2026 EASD symposium slot to present clinical data on UP421 hypoimmune allogeneic islet transplantation without immunosuppression.
- Presentation will outline a path toward durable immune-evasive islet grafts, supporting a strategy to broaden cell therapy use in type 1 diabetes.
- Focus remains on engineered-cell medicines, with platform work aimed at replacing damaged cells and scaling availability to more patients.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved